This is quite a new clinical trial, this is with a new compound called invikafusp. Invikafusp is a bispecific monoclonal antibody that tried to reinvigorate anti-tumour T-cell responses. The clinical trial is very interesting because although it is a early phase, several patients with solid tumours, including patients with GI malignancies, were included in the clinical trial. The trial demonstrated benefit in terms of overall response rate for these patients that, as mentioned, included not only colorectal cancer but also other GI tumours, specifically patients as well with an MSI high status. It described a response rate of between 23-25% and a disease control rate of 63% which is huge for a clinical trial in a heavily pretreated population with this particular compound.

What is the significance of these results and what is next for this study?

What we have seen with this clinical trial is that the compound has activity in this heavily pretreated population so probably the next step is to better study this particular compound in some patients, like is the case of patients with colorectal cancer, maybe with a better selection, for example, those patients with a high mutational burden and maybe low tumour burden. Because we have seen that for those patients that are carrying a tumour without MSI conditions, being MSS but without liver mets or what it could be low tumour burden, could have the chance to respond to this particular compound.

So the next step is to see the results of the expansion cohort with more patients with GI tumours and colorectal cancer illness and see the efficacy in patients with this particular molecular profile and clinical profile.